# Atrial septal defect closure as second-line therapy in refractory heart failure: a successful case report in a 6-year-old child with phosphoglucomutase 1 deficiency (PGM1-CDG)

**Authors:** Sofiane Mimoun, Alban-Elouen Baruteau, Bruno Lefort, Céline Grunenwald, Werner Oscar

PMC · DOI: 10.1093/ehjcr/ytaf583 · European Heart Journal. Case Reports · 2025-11-06

## TL;DR

A 6-year-old child with a rare metabolic disorder and heart failure improved after closing a heart defect, offering a new treatment option for similar cases.

## Contribution

Demonstrates ASD closure as a viable second-line therapy for refractory heart failure in a patient with PGM1-CDG.

## Key findings

- ASD closure led to rapid weaning from inotropes and full clinical recovery in a child with PGM1-CDG.
- Balloon occlusion testing was essential to confirm the feasibility of ASD closure and guide device use.
- At 6-month follow-up, left ventricular function was normalized and the patient remained asymptomatic.

## Abstract

Atrial septal defect (ASD) is a common congenital heart defect that remains mainly asymptomatic in childhood. However, when left ventricular (LV) compliance is impaired, as in myocarditis or cardiomyopathy, ASD may lead to severe heart failure due to increased left-to-right shunting and a reduced systemic cardiac output.

We report the case of a 6-year-old boy with CDG-PGM1 and a large ASD who developed acute refractory heart failure, likely triggered by Parvovirus B19 myocarditis. Despite optimal medical therapy, including immunoglobulins, inotropes, and heart failure medication, he remained dependent on pharmacological support. He was deemed ineligible for heart transplantation due to his underlying metabolic condition; therefore an ASD closure was questioned as a last therapeutic option. A balloon occlusion test showed a mild increase in LV end-diastolic pressure, allowing percutaneous closure using a hand-made fenestrated device. The procedure was successful, leading to rapid weaning from inotropes and full clinical recovery. At 6-month follow-up, LV function was normalized, and the patient was asymptomatic.

In selected patients with impaired LV compliance, ASD closure may offer a life-saving therapeutic option. Haemodynamic evaluation with balloon occlusion testing is essential to evaluate closure feasibility and determine the potential need of using a fenestrated device.

## Linked entities

- **Genes:** PGM1 (phosphoglucomutase 1) [NCBI Gene 5236]
- **Diseases:** phosphoglucomutase 1 deficiency (MONDO:0013968), atrial septal defect (MONDO:0006664), myocarditis (MONDO:0004496), cardiomyopathy (MONDO:0004994), heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** PGM1 (phosphoglucomutase 1) [NCBI Gene 5236] {aka CDG1T, GSD14}
- **Diseases:** impaired LV compliance (MESH:D018487), congenital heart defect (MESH:D006330), myocarditis (MESH:D009205), heart failure (MESH:D006333), phosphoglucomutase 1 deficiency (MESH:C567859), ASD (MESH:D006344), cardiomyopathy (MESH:D009202)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human parvovirus B19 (no rank) [taxon 10798]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12644980/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12644980/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12644980/full.md

---
Source: https://tomesphere.com/paper/PMC12644980